Despite large coverage with efficacious vaccines, whooping cough is still a major cause of global childhood morbidity and mortality. In an effort to solve this problem, the Child-Innovac programme has developed a new vaccine designed to be given as a single dose at birth in order to protect young children, under 6 months of age, which is the most vulnerable age group and not sufficiently protected by the current vaccines. The new vaccine is based on a novel concept of nasal administration of the live genetically attenuated whooping cough agent, which in pre-clinical animal tests has been shown to be perfectly safe and able to induce strong, rapid and long-lasting protection against the infection. Within the frame of the Child- Innovac project, this vaccine will now be administered for the first time to man. If successful, it will constitute a novel platform to vaccinate by nasal administration against a number of different respiratory infections and other diseases.